News & Events | Cellular Origins

Key takeaways from Advanced Therapies Europe

Cellular Origins and 3P innovation collaborate to accelerate industrialisation of CGT manufacturing

Cellular Origins Appoints Geoffrey Hodge as Non-Executive Director

Cellular Origins Acquires ACTIA Platform IP to enhance automated cell therapy manufacturing

Cellular Origins and Cell and Gene Therapy Catapult collaborate to demonstrate universal automation of CGT manufacturing

ISCT Vancouver 2024

ACHEMA 2024

Meet Szer Ming Lee, Head of Software at Cellular Origins

Cellular Origins awarded highly commended in ‘The Award for Innovation’ at this year’s Cambridge Independent Science and Technology Awards

Cellular Origins, a TTP Company, appoints Peter Crossley as Chief Operating Officer

Meet Jason Jones, Global Business Development Lead at Cellular Origins

Cellular Origins, a TTP Company, establishes Advisory Board of global industry leaders

Advanced Therapies Week 2024

Keeping Up with the Pace in a Rapidly Changing Industry: Innovative Solutions for Cell and Gene Therapy Developers

Drug Digest: Improving Aseptic Processing and Manufacturing Needs

BioPharm International: Automation Aids Cell and Gene Therapy Production

BioPharm International: Expanding the Emerging Therapeutic Horizon

Advanced Therapies Week: Building Infrastructure and Capacity Panel Session

Cellular Origins launches Constellation™, its configurable robotic platform to enable scalable manufacture of advanced therapies

ISCT 2023 Paris Annual Meeting

Cellular Origins partners with ScaleReady to simplify, standardise, and automate cell therapy manufacturing

Labiotech: Where is innovation needed in cell therapy?

Beyond Biotech podcast 36: Bio-Europe Spring and Cellular Origins

Constellation featured in Science: Configurable Robotic Platform For Advanced Therapy Manufacturing

GEN: Cell and Gene Therapy Scale-Up Challenges

No More Sleepwalking: New Mindsets for Manufacturing Cell and Gene Therapies at Commercial Scale

TTP introduces cellular origins a TTP company focussed on delivering scalable manufacture of cell and gene therapies

What failure rate are we willing to accept in cell therapy manufacture? Insights from medical device development

UK Innovation corridor ‘critical’ to development of cell and gene therapy, TTP plc summit told

Video Interview: Talking Cell Therapy Trends – Edd Stone of TTP explains how the industry is overcoming the manufacturing challenges associated with cell therapies

Medicine Maker: How do we ensure that not only the rich benefit from cell and gene therapy?

What can our experience of traditional bioprocessing teach us about the manufacturing of new cell therapies?

Predicting failure rates in cell therapy manufacturing is one in a million good enough

GEN: Technological Advances Facilitate Autologous Cell Therapy Scale-Out

Who should lead the charge in cell therapy manufacturing

Cell therapy scaling beyond the biology

Cell therapies have shown the ability to cure the incurable, and yet we cannot get them to patients because of an inability to scale manufacturing. At Cellular Origins, we want therapy developers to be able to scale the processes they have tried, tested and proven. And then in the future, as further technologies emerge that further enhance the efficacy of these therapies, we want to ensure that these too can be manufactured for patients everywhere.

Dr Edwin Stone | CEO | Cellular Origins

As featured in: